Fundraising Fox

AmplifiDx

Pleasanton, US · Founded 2020 · Delaware corporation · 3 known investors

AmplifiDx develops point-of-care molecular diagnostic tests and its DX 100 platform for family, women's, and sexual health, targeting infectious disease detection for healthcare professionals and patients. The multiplex platform can detect up to 10 analytes with rapid results and minimal hands-on time.

BiotechDigital HealthFemTechHealthtechMedical Devices

Founders & leadership

NSNancy Schoenbrunner
Nancy SchoenbrunnerChief Executive Officer
SDShoulian Dong
Shoulian DongChief Scientific Officer
DSDaniel Schoener
Daniel SchoenerChief Product Officer
CMChris Meda
Chris MedaChief Commercial Officer
MT
Ming TanNamed on SEC filing
SD
Sammy DatwaniNamed on SEC filing
BS
Bruce SargeantNamed on SEC filing

Investors · 3

Beacon AngelsBoston · $50K – $400K
Social StartsSan Francisco
Shepherd VenturesreportedSan Diego · $750K – $3M

Reported raises · per SEC filings

Form D private placements

$329.4K disclosed across 1 of 2 rounds · 2021–2024

▶$329.4KraisedJul 2021 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Nancy SchoenbrunnerExecutive Officer, Director
  • Ming TanDirector
  • Sammy DatwaniDirector
  • Bruce SargeantDirector
Offering amount
$2.1M
Amount sold
$329.4K
Minimum investment
$1
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Digital Diagnostics14 shared keywordsHealthcare technology company whose FDA-cleared autonomous AI diagnoses diabetic retinopathy from retinal images at the point of care.
CareDx9 shared keywordsCareDx provides molecular diagnostic testing, workflow software, patient support, and pharmacy services for care teams working in transplant, cell therapy, and specialty oncology. Its products support rejection monitoring and complex care management in precision medicine.
Foresight Dx9 shared keywordsForesight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types. Its offerings support oncology drug development, clinical trials, and patient care for academic and biopharma partners.
Earlydx8 shared keywordsEarlyDx develops non-invasive liquid biopsy tests aimed at early cancer detection and precision medicine. The company positions its tests as accurate and affordable diagnostics.
Athenahealth Inc7 shared keywordsCloud-based healthcare platform for clinical workflows

Companies competing with AmplifiDx for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$286.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$400K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Shepherd Ventures III portfolio company AmplifiDX Secures Added Non-Dilutive Funding - Akron Beacon Journal - Press Releasesbeaconjournal.com · Apr 2026AmplifiDx Secures Additional $954,213 in Non-Dilutive Funding from NIH’s RADx Tech Program to Advance U.S. COVID-19 Testing Capabilities. — AmplifiDxamplifidx.com · Dec 2024AmplifyDx - FreeMind Elite - FreeMind Groupfreemindgroup.com · Nov 2023Press Release - AmplifiDx Secures $1.38 M to Develop Groundbreaking Molecular Point-of-Care System — AmplifiDxamplifidx.com · May 2019

Frequently asked questions

What does AmplifiDx do?
AmplifiDx develops point-of-care molecular diagnostic tests and its DX 100 platform for family, women's, and sexual health, targeting infectious disease detection for healthcare professionals and patients. The multiplex platform can detect up to 10 analytes with rapid results and minimal hands-on time.
Who are AmplifiDx's investors?
AmplifiDx's investors include Beacon Angels, Social Starts, Shepherd Ventures.
How much funding has AmplifiDx raised?
AmplifiDx has disclosed $329.4K raised across 1 of its 2 known rounds.
Where is AmplifiDx headquartered?
AmplifiDx is headquartered in Pleasanton, US.